Related Experiment Video
Updated: Jan 10, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
RNA-based cancer vaccines: mechanisms, clinical progress, and translational challenges
Aya Y Al-Kabariti1, Munthar Abosaoda Kadhim2,3, Hayjaa Mohaisen Mousa4
1Faculty of Pharmacy, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
Abstract:
Recent advancements in vaccine technology have led to the development of RNA-based vaccines, including mRNA, circular RNA, and self-amplifying mRNA, which have emerged as a promising platform for tumor prevention and treatment. In comparison with conventional antitumor vaccines, such as whole cell, peptide, and DNA vaccines, RNA vaccines possess several advantageous characteristics. They have the capacity to encode multiple antigens, induce robust immune responses, and can be developed more expeditiously. Additionally, RNA vaccines have the potential for scalable manufacturing with acceptable safety profiles in cancer patients. Preliminary investigations, conducted both in preclinical and clinical settings, have yielded encouraging outcomes for RNA vaccines in the context of diverse tumor types. This review delineates the types, advances, and applications of RNA vaccines in antitumor therapy, as well as the challenges associated with their use. Finally, it introduces future technological directions for improving these current vaccine platforms for a wide range of therapeutic uses.
Insights
RNA vaccines, including mRNA, offer a promising new approach for cancer treatment and prevention. These advanced vaccines induce strong immune responses and show potential for scalable manufacturing and safety in patients.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- RNA-based vaccines (mRNA, circular RNA, self-amplifying mRNA) represent a significant advancement in vaccine technology.
- These platforms are being explored for their potential in tumor prevention and treatment.
- RNA vaccines offer advantages over conventional antitumor vaccines like peptide and DNA vaccines.
Purpose of the Study:
- To review the types, advances, and applications of RNA vaccines in antitumor therapy.
- To discuss the challenges associated with RNA vaccine development and use.
- To explore future technological directions for enhancing RNA vaccine platforms.
Main Methods:
- This review synthesizes information from preclinical and clinical investigations.
- It analyzes the characteristics and potential of various RNA vaccine modalities.
- The review examines the application of RNA vaccines across diverse tumor types.
Main Results:
- RNA vaccines demonstrate the capacity to encode multiple antigens and elicit robust immune responses.
- Preliminary studies show encouraging outcomes for RNA vaccines in various cancer types.
- RNA vaccines offer potential for rapid development, scalable manufacturing, and acceptable safety profiles.
Conclusions:
- RNA vaccines are a promising platform for cancer immunotherapy, offering unique advantages.
- Further technological development is needed to overcome current challenges and optimize efficacy.
- RNA vaccine technology holds significant potential for broad therapeutic applications in oncology.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mechanisms of Retrovirus-induced Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Microorganisms in Medicine and Therapeutics
Cancer